Literature DB >> 29327160

Differences in histological features and PD-L1 expression between sporadic microsatellite instability and Lynch-syndrome-associated disease in Japanese patients with colorectal cancer.

Rin Yamada1, Tatsuro Yamaguchi2,3,4, Takeru Iijima5, Rika Wakaume5, Misato Takao6, Koichi Koizumi7, Tsunekazu Hishima1, Shin-Ichiro Horiguchi1.   

Abstract

BACKGROUND: The field of immunotherapy has recently focused on cancers with microsatellite instability (MSI). These cancers include both Lynch-syndrome-associated tumors, which are caused by mismatch repair (MMR) germline mutations, and sporadic MSI tumors, which are mainly attributed to MLH1 promoter methylation. The present study aimed to clarify differences in the histological and PD-L1 expression profiles between these two types of MSI cancers in Japanese patients.
METHODS: Among 908 cases of colorectal cancer treated via surgical resection from 2008 to 2014, we identified 64 MSI cancers, including 36 sporadic MSI and 28 Lynch-syndrome-associated cancers, using a BRAF V600E mutation analysis and MLH1 methylation analysis. Of the latter subgroup, 21 (75%) harbored MMR germline mutations.
RESULTS: The following were more frequent with sporadic MSI than with Lynch syndrome associated cancers: poor differentiation (50.0 vs. 7.1%, P = 0.0002), especially solid type (30.6 vs. 3.6%, P = 0.0061); medullary morphology (19.4 and 0%, P = 0.015), Crohn-like lymphoid reaction (50.0 vs. 25.0%, P = 0.042), and PD-L1 expression (25.0 vs. 3.6%, P = 0.034). However, the groups did not differ in terms of the mean invasive front and intratumoral CD8-positive cell densities. In a logistic regression analysis, PD-L1 expression correlated with poor differentiation (odds ratio: 7.65, 95% confidence interval: 1.55-37.7, P = 0.012), but not with the difference between sporadic MSI cancer and Lynch-syndrome-associated cancer (odds ratio: 4.74, 95% confidence interval: 0.50-45.0, P = 0.176).
CONCLUSIONS: Therefore, compared with Lynch-syndrome-associated cancers, sporadic MSI cancers are more frequently solid, poorly differentiated medullary cancers that express PD-L1.

Entities:  

Keywords:  Colorectal cancer; Lynch syndrome; Microsatellite instability; PD-L1

Mesh:

Substances:

Year:  2018        PMID: 29327160     DOI: 10.1007/s10147-018-1238-y

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.402


  38 in total

1.  Colorectal Cancer with BRAF D594G Mutation Is Not Associated with Microsatellite Instability or Poor Prognosis.

Authors:  Misato Amaki-Takao; Tatsuro Yamaguchi; Soichiro Natsume; Takeru Iijima; Rika Wakaume; Keiichi Takahashi; Hiroshi Matsumoto; Michiko Miyaki
Journal:  Oncology       Date:  2016-07-13       Impact factor: 2.935

2.  Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies.

Authors:  M Ilie; E Long-Mira; C Bence; C Butori; S Lassalle; L Bouhlel; L Fazzalari; K Zahaf; S Lalvée; K Washetine; J Mouroux; N Vénissac; M Poudenx; J Otto; J C Sabourin; C H Marquette; V Hofman; P Hofman
Journal:  Ann Oncol       Date:  2015-10-19       Impact factor: 32.976

3.  Precision and performance characteristics of bisulfite conversion and real-time PCR (MethyLight) for quantitative DNA methylation analysis.

Authors:  Shuji Ogino; Takako Kawasaki; Mohan Brahmandam; Mami Cantor; Gregory J Kirkner; Donna Spiegelman; G Mike Makrigiorgos; Daniel J Weisenberger; Peter W Laird; Massimo Loda; Charles S Fuchs
Journal:  J Mol Diagn       Date:  2006-05       Impact factor: 5.568

4.  Features of colorectal cancers with high-level microsatellite instability occurring in familial and sporadic settings: parallel pathways of tumorigenesis.

Authors:  J Young; L A Simms; K G Biden; C Wynter; V Whitehall; R Karamatic; J George; J Goldblatt; I Walpole; S A Robin; M M Borten; R Stitz; J Searle; D McKeone; L Fraser; D R Purdie; K Podger; R Price; R Buttenshaw; M D Walsh; M Barker; B A Leggett; J R Jass
Journal:  Am J Pathol       Date:  2001-12       Impact factor: 4.307

Review 5.  A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer.

Authors:  C R Boland; S N Thibodeau; S R Hamilton; D Sidransky; J R Eshleman; R W Burt; S J Meltzer; M A Rodriguez-Bigas; R Fodde; G N Ranzani; S Srivastava
Journal:  Cancer Res       Date:  1998-11-15       Impact factor: 12.701

6.  PD-L1 expression in colorectal cancer is associated with microsatellite instability, BRAF mutation, medullary morphology and cytotoxic tumor-infiltrating lymphocytes.

Authors:  Matthew W Rosenbaum; Jacob R Bledsoe; Vicente Morales-Oyarvide; Tiffany G Huynh; Mari Mino-Kenudson
Journal:  Mod Pathol       Date:  2016-05-20       Impact factor: 7.842

7.  Tumour CD274 (PD-L1) expression and T cells in colorectal cancer.

Authors:  Yohei Masugi; Reiko Nishihara; Juhong Yang; Kosuke Mima; Annacarolina da Silva; Yan Shi; Kentaro Inamura; Yin Cao; Mingyang Song; Jonathan A Nowak; Xiaoyun Liao; Katsuhiko Nosho; Andrew T Chan; Marios Giannakis; Adam J Bass; F Stephen Hodi; Gordon J Freeman; Scott Rodig; Charles S Fuchs; Zhi Rong Qian; Shuji Ogino
Journal:  Gut       Date:  2016-05-05       Impact factor: 23.059

8.  Value of histopathology in predicting microsatellite instability in hereditary nonpolyposis colorectal cancer and sporadic colorectal cancer.

Authors:  Jinru Shia; Nathan A Ellis; Philip B Paty; Garrett M Nash; Jing Qin; Kenneth Offit; Xin-Min Zhang; Arnold J Markowitz; Khedoudja Nafa; Jose G Guillem; W Douglas Wong; William L Gerald; David S Klimstra
Journal:  Am J Surg Pathol       Date:  2003-11       Impact factor: 6.394

9.  Microsatellite instability is associated with tumors that characterize the hereditary non-polyposis colorectal carcinoma syndrome.

Authors:  P Peltomäki; R A Lothe; L A Aaltonen; L Pylkkänen; M Nyström-Lahti; R Seruca; L David; R Holm; D Ryberg; A Haugen
Journal:  Cancer Res       Date:  1993-12-15       Impact factor: 12.701

10.  Temporal and spatial discordance of programmed cell death-ligand 1 expression and lymphocyte tumor infiltration between paired primary lesions and brain metastases in lung cancer.

Authors:  A S Mansfield; M C Aubry; J C Moser; S M Harrington; R S Dronca; S S Park; H Dong
Journal:  Ann Oncol       Date:  2016-08-08       Impact factor: 32.976

View more
  7 in total

1.  Familial Lynch syndrome with early age of onset and confirmed splice site mutation in MSH2: A case report.

Authors:  Zornitsa Bogomilova Kamburova; Savelina Lubenova Popovska; Katya Stefanova Kovacheva; Krasimir Todorov Petrov; Slavena Enkova Nikolova
Journal:  Biomed Rep       Date:  2022-03-14

Review 2.  Diagnosis of Lynch Syndrome and Strategies to Distinguish Lynch-Related Tumors from Sporadic MSI/dMMR Tumors.

Authors:  Julie Leclerc; Catherine Vermaut; Marie-Pierre Buisine
Journal:  Cancers (Basel)       Date:  2021-01-26       Impact factor: 6.639

3.  Sidedness determines clinical characteristics and survival outcomes in medullary adenocarcinoma of the colon.

Authors:  Andrew M Blakely; Rebecca A Nelson; Stanley A Hamilton; Lily L Lai
Journal:  Sci Rep       Date:  2021-10-14       Impact factor: 4.379

Review 4.  New Potential Immune Biomarkers in the Era of Precision Medicine: Lights and Shadows in Colorectal Cancer.

Authors:  Angela Damato; Martina Rotolo; Francesco Caputo; Eleonora Borghi; Francesco Iachetta; Carmine Pinto
Journal:  Life (Basel)       Date:  2022-07-28

Review 5.  Epigenetic modifications: Critical participants of the PD‑L1 regulatory mechanism in solid tumors (Review).

Authors:  Xiaoran Ma; Jibiao Wu; Bin Wang; Cun Liu; Lijuan Liu; Changgang Sun
Journal:  Int J Oncol       Date:  2022-09-21       Impact factor: 5.884

Review 6.  An Update on Immune Checkpoint Therapy for the Treatment of Lynch Syndrome.

Authors:  Christina Therkildsen; Lars Henrik Jensen; Maria Rasmussen; Inge Bernstein
Journal:  Clin Exp Gastroenterol       Date:  2021-05-24

7.  Clinicopathological and prognostic significance of PD-L1 expression in colorectal cancer: a meta-analysis.

Authors:  Shuxia Wang; Bo Yuan; Yun Wang; Mingyang Li; Xibo Liu; Jing Cao; Changtian Li; Jihong Hu
Journal:  Int J Colorectal Dis       Date:  2020-09-10       Impact factor: 2.571

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.